Asheesh Dewan, MD
Pediatric Endocrinology · Las Vegas, NVNPI 1740352699
Payments from drug & device makers
Across 1,295 payments — averaging $830.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$296K
- Novo Nordisk$183K
- Mannkind Corporation$168K
- Ascendis Pharma Endocrinology Inc$142K
- Abbott$111K
- Novo Nordisk AS$110K
- plus $65K from 46 others
Across 3 payments — averaging $60.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mannkind Corporation$183
What the payments were for
- Consulting fees$30,41711%
- Speaking & faculty fees$197,76772%
- Travel & lodging$26,05010%
- Food & beverage$18,8527%
- Education$890%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$72,868
- RYBELSUS$60,552
- SKYTROFA$53,412
- Tresiba$15,853
- Sogroya$6,786
- NGENLA$5,710
- Triptodur$4,541
- Xultophy 100/3.6$2,210
- Norditropin$1,806
- t:slim X2 insulin pump$1,650
- Minimed 670G System$718
- TZIELD$641
- Strensiq$525
- MINIMED 780G$428
- iLet Bionic Pancreas$338
- Omnipod$298
- SpiderFX$174
- Alkindi$166
- KHINDIVI$166
- INCRELEX$166
How this compares
Too few pediatric endocrinology providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $88,734 |
| MounjaroTirzepatide | 55 | $74,365 |
| TrulicityDulaglutide | 27 | $33,874 |
| JardianceEmpagliflozin | 30 | $29,024 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $20,540 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $17,527 |
| FarxigaDapagliflozin Propanediol | 15 | $8,703 |
| Novolog FlexpenInsulin Aspart | 24 | $5,851 |
| Advocate Pen NeedlePen Needle, Diabetic | 19 | $5,632 |
| VascepaIcosapent Ethyl | 11 | $3,928 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $3,219 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,534 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 16 | $1,648 |
| Testosterone Cypionate | 16 | $599 |
| Ondansetron OdtOndansetron | 20 | $464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $301 | $108,23982 claims |
| Novo NordiskOzempic | $182,560 | $88,73477 claims |
| Boehringer IngelheimJardiance | $37 | $29,02430 claims |
| AstraZenecaFarxiga | $1,525 | $8,70315 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $76 | $44873 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric endocrinology providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other pediatric endocrinology in Las Vegas
- Carron SchweigerLas Vegas$8K
- Jeremiah NelsonLas Vegas$2K
- Anamaria ManeaReno$23K
- Alexandra AguilarHenderson$7K
- Arushi VermaReno$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.